{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:37:58Z","timestamp":1786649878542,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>Autoimmune hemolytic anemia (AIHA) is an acquired hemolytic disorder caused by autoantibodies and\/or complement-mediated destruction of red blood cells (RBCs), often driven by dysregulated B lymphocyte activity. A notable clinical association exists between AIHA and lymphoproliferative disorders (LPD), particularly chronic lymphocytic leukemia, and non-Hodgkin\u2019s lymphoma (NHL). To summarize the clinicopathological link, prevalence, pathogenesis, and management strategies of AIHA associated with NHL. This narrative review synthesizes evidence from 20 peer-reviewed studies published between 2011 and 2024, identified through PubMed, Google Scholar, and manual citation tracking. Eligible studies were restricted to English-language articles addressing the prevalence, pathogenesis, clinical features, diagnosis, or treatment of AIHA in NHL. Approximately 7%\u201310% of NHL patients develop coexisting AIHA, while up to 20% of AIHA patients are eventually diagnosed with lymphoma. The reported incidence of AIHA among NHL patients varies widely (0.23%\u201315.7%), reflecting methodological and population differences. Proposed mechanisms include chronic antigen stimulation and dysregulated antibody production. The coexistence of both conditions complicates management: Treatment generally prioritizes NHL-directed therapy, while glucocorticoids and rituximab are commonly used for AIHA control. AIHA and NHL share overlapping immunopathological pathways with important clinical implications. Early recognition of AIHA in NHL is essential to optimize patient outcomes. Future priorities include developing biomarkers to identify high-risk patients and conducting large-scale randomized trials to validate complement inhibitors for cold agglutinin disease (CAD).<\/jats:p>","DOI":"10.4103\/njcp.njcp_826_24","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T13:00:08Z","timestamp":1767013208000},"page":"1359-1363","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Autoimmune Hemolytic Anemia in Non-Hodgkin\u2019s Lymphoma: Pathogenesis, Diagnosis, and Management"],"prefix":"10.4103","volume":"28","author":[{"given":"KD","family":"Suryana","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Hemato-Oncology, Dharmais Cancer Center Hospital, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Alodia","sequence":"additional","affiliation":[{"name":"Medical Education Program, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"R1-20260116","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/bloodadvances.2019000036","article-title":"Defining autoimmune hemolytic anemia: A systematic review of the terminology used for diagnosis and treatment","volume":"3","author":"Hill","year":"2019","journal-title":"Blood Adv"},{"key":"R2-20260116","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/asheducation-2018.1.382","article-title":"Autoimmune hemolytic anemia","volume":"2018","author":"Hill","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R3-20260116","doi-asserted-by":"crossref","first-page":"e19015","DOI":"10.1097\/MD.0000000000019015","article-title":"Clinical analysis of 20 patients with non-Hodgkin lymphoma and autoimmune hemolytic anemia: A retrospective study","volume":"99","author":"Zhou","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R4-20260116","doi-asserted-by":"crossref","first-page":"19716","DOI":"10.1038\/s41598-019-56162-y","article-title":"Characteristics of patients with autoimmune haemolytic anaemia secondary to lymphoproliferative disorder: A single-centre retrospective analysis","volume":"9","author":"Xing","year":"2019","journal-title":"Sci Rep"},{"key":"R5-20260116","first-page":"5580823","article-title":"Autoimmune hemolytic anemia as presenting symptom of Hodgkin lymphoma","volume":"2021","author":"Burley","year":"2021","journal-title":"Case Rep Hematol"},{"key":"R6-20260116","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12979-020-00208-7","article-title":"Autoimmune hemolytic anemia: Current knowledge and perspectives","volume":"17","author":"Michalak","year":"2020","journal-title":"Immun Ageing"},{"key":"R7-20260116","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000439002","article-title":"New insights in the pathogenesis of autoimmune hemolytic anemia","volume":"42","author":"Barcellini","year":"2015","journal-title":"Transfus Med Hemother"},{"key":"R8-20260116","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/1744666X.2022.2089115","article-title":"Autoimmune hemolytic anemia: Causes and consequences","volume":"18","author":"Fattizzo","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"R9-20260116","first-page":"e22938","article-title":"A practical perspective of the hematologic manifestations of systemic lupus erythematosus","volume":"14","author":"Santacruz","year":"2022","journal-title":"Cureus"},{"key":"R10-20260116","first-page":"8870643","article-title":"Rheumatoid arthritis and autoimmune hemolytic anemia as first manifestation of rhupus","volume":"2020","author":"Espinosa-Orantes","year":"2020","journal-title":"Case Rep Rheumatol"},{"key":"R11-20260116","doi-asserted-by":"crossref","first-page":"194542","DOI":"10.1155\/2013\/194542","article-title":"Graves\u2019 disease causing pancytopenia and autoimmune hemolytic anemia at different time intervals: A case report and a review of the literature","volume":"2013","author":"Naji","year":"2013","journal-title":"Case Rep Med"},{"key":"R12-20260116","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.12998\/wjcc.v10.i4.1286","article-title":"Iguratimod in treatment of primary Sj\u00f6gren\u2019s syndrome concomitant with autoimmune hemolytic anemia: A case report","volume":"10","author":"Zhang","year":"2022","journal-title":"World J Clin Cases"},{"key":"R13-20260116","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.3390\/ijms25084296","article-title":"Autoimmune hemolytic anemias: Classifications, pathophysiology, diagnoses and management","volume":"25","author":"Loriamini","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R14-20260116","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3389\/fimmu.2020.00946","article-title":"The changing landscape of autoimmune hemolytic anemia","volume":"11","author":"Barcellini","year":"2020","journal-title":"Front Immunol"},{"key":"R15-20260116","doi-asserted-by":"crossref","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"key":"R16-20260116","doi-asserted-by":"crossref","first-page":"960137","DOI":"10.1155\/2011\/960137","article-title":"Use of rituximab in autoimmune hemolytic anemia associated with non-hodgkin lymphomas","volume":"2011","author":"Fozza","year":"2011","journal-title":"Adv Hematol"},{"key":"R17-20260116","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/bjh.14654","article-title":"Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia","volume":"177","author":"Hill","year":"2017","journal-title":"Br J Haematol"},{"key":"R18-20260116","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in cold agglutinin disease","volume":"384","author":"R\u00f6th","year":"2021","journal-title":"N Engl J Med"},{"key":"R19-20260116","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1182\/bloodadvances.2022009318","article-title":"Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up","volume":"7","author":"R\u00f6th","year":"2023","journal-title":"Blood Adv"},{"key":"R20-20260116","doi-asserted-by":"crossref","first-page":"102733","DOI":"10.1016\/j.eclinm.2024.102733","article-title":"Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B","volume":"74","author":"R\u00f6th","year":"2024","journal-title":"eClinicalMedicine"}],"container-title":["Nigerian Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_826_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:59:27Z","timestamp":1786647567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_826_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/njcp.njcp_826_24","relation":{},"ISSN":["1119-3077","2229-7731"],"issn-type":[{"value":"1119-3077","type":"print"},{"value":"2229-7731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2024-12-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}